A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion

Détails de l’essai

Phase 2

Phase
Sexe(s)
18+

Tranche d’âge
43

Site(s)
Pas encore de recrutement

Options de traitement

Bras de l’étude

INTERVENTION ASSIGNÉE

Experimental: Arm A: BMS-986504 Dose 1

Drug: BMS-986504

Experimental: Arm B: BMS-986504 Dose 2

Drug: BMS-986504

Principaux critères d’éligibilité

Inclusion Criteria: - Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation. - Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition). - At least 1 measurable lesion as per RECIST v1.1. - Documented radiographic disease progression on or after the most recent line of treatment. - Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. - Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF. - Capability to swallow tablets intact (without chewing or crushing). Exclusion Criteria: - Active brain metastases or carcinomatous meningitis. - History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. - Prior treatment with a PRMT5 or MAT2A inhibitor. - Known severe hypersensitivity to study treatment and/or any of its excipients. - Other protocol-defined inclusion/exclusion criteria apply.

Résumé imprimable

Détails de l’essai

Options de traitement

Principaux critères d’éligibilité